Table 3.
Complications and Treatment.
| Wang L et al. [10] | Zhu X et al. [11] | Lian J et al. [12] |
Chen T et al. [14] | Liu K et al. [15] |
Godaert L et al. [16] |
Liu Y et al. [17] |
Mi B et al. [18] |
Graselli G et al. [21] |
Yuan Y et al. [28] | Guo T et al. [24] |
Bruno G et al. [26] |
Gold J et al. [27] |
Richardson S et al. [29] |
||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Publication Month - 2020 | Mar | Mar | Mar | Apr | Mar | Apr | Mar | Apr | Apr | Mar | May | May | May | Apr | |
| Country | China | China | China | China | China | France | China | China | Italy | China | China | Italy | USA | USA | |
| No. Patients ≥60 Years Old | 339 | 114 | 136 | 55 | 18 | 17 | 7 | 6 | 961 | 4 | 105 | 31 | 117 | 2582 | |
| Age | >60 | >70 | ≥60 | ≥65 | ≥60 | >67 | >61 | >75 | ≥61 | 64-71 | ≥ 60 | ≥65 | ≥65 | >65 | |
| Male | 166 | 67 | 58 | 34 | 12 | 8 | 4 | 2 | 783 | 2 | 48 | 19 | - | - | |
| Symptoms No. | Table 1 | Table 1 | Table 1 | Table 1 | Table 1 | Table 1 | Table 1 | Table 1 | Table 1 | Table 2 | Table 1 | Table 1 | Table 1 | - | |
| Comorbidities No. | - | ||||||||||||||
| Outcome No. | 676 Discharged 1487 (613 ICU) Hospitalized 419 Death |
||||||||||||||
| Hospital Stay duration (days) - Median (IQR) | Discharged: 4.5 (2.7 - 7.2) Still hospitalized: 4.4 (2.3-8.0) Dead: 4.4 (2.1 - 7.1) |
||||||||||||||
| Complications*(%) | Most common complications of patients ≥60 years old | ||||||||||||||
| (42) SI |
- | (17) ARDS |
- | (39) HI |
(59) RI |
(100) Pn |
(33) SI |
- | - | (10) ARDS |
(35) ARDS |
- | (30) RI |
||
| (29) HI |
- | (10) RI |
- | (39) RI |
(47) HI |
(86) ARDS |
- | - | - | (5) AHI |
(29) SI |
- | - | ||
| (21) ARDS |
- | (10) HI |
- | (22) SI |
- | (43) RF |
- | - | - | (5) RI |
(10) Sh |
- | - | ||
| (21) AHI |
- | - | (22) ARDS |
- | (29) RI |
- | - | - | (1) HI |
(1) AHI |
- | - | |||
| (17) CI |
- | - | - | (17) AHI |
- | (29) HI |
- | - | - | - | - | - | - | ||
| Others | (8) RI | - | - | - | - | (29) SI (14) CI (14) Sh |
- | - | - | - | - | - | - | ||
| ≤5 % | Sh | Sh | Sh | HI | |||||||||||
| Treatment** (%) | |||||||||||||||
| - | (97) AvT | (86) AvT | (62) Ster |
(89) LR | - | (100) Rv |
(100) AvT | - | (75) LR |
(93) AvT |
(68) AbT |
- | - | ||
| - | (85) AbT |
(50) IFN | (27) IFN | (67) AbT |
- | (100) IFN | (100) AbT |
- | (75) Ig |
(60) AbT |
(61) LR |
- | - | ||
| - | (45) Ig | (31) Um | (18) LR | (33) IFN | - | (57) Ig |
(50) Ster |
- | (50) Um | (49) Ster |
(55) Ster |
- | - | ||
| - | - | (18) Ig | (13) Um | (22) Ig | - | (57) Os |
(33) Ig | - | (50) Cef |
(43) Ig |
- | - | - | ||
| - | - | (9) LR | (9) Ig |
- | (43) Ster |
- | (50) Moxi | - | - | - | - | ||||
| - | - | - | - | - | - | - | - | - | (25) Os |
- | - | - | - | ||
| - | - | - | - | - | - |
- |
- | - | (25) IFN | - | - | - | - | ||
| - | - | - | - | - |
- |
- | (25) Lin |
- | - | - | - | ||||
| Supplementary Oxygen No. (%) | - | 104 (91) | - | 49 (89) | 17 (95) | 8 (47) |
- | 6 (100) | 615 (64) |
- | 89 (85) | 28 (90) | 104 (89) | - | |
| Mechanical Ventilation (MV) ° No. (%) | - | - | - | 24 (44) | - | - | 6 (86) | - | - | - | - | - | - | - | |
| Invasive MV | - | - | 6 (5) | - | 4 (22) | - | 3 (43) | 0 | 709 (74) | - | 8 (8) | 8 (26) | 48 (41) | 558 (22) | |
| Non-Invasive MV | - | - | 3 (2) | - | 1 (6) | - | - | 3 (50) | 80 (8) | - | 7 (7) | - | 5 (4) | - | |
| Other Treatments°° (%) | - | (70) TCM (50) HT (28) VD (3) Hem |
- | (55) MA (9) ThyF |
(78) ThyP (78) TCM (11) RRT (6) ECMO |
- | - | - | - | (75) ThyF (75) Chlor (75) S |
(64) NCa (3) ECMO |
(77) HyC (74) Hep (13) Toc |
(82) NCa (11) RRT (43) VS (7) CPR |
(4) RRT |
|
Abbreviations
Complications: Pn; Pneumonia, CI; Cardiac Insufficiency, ARDS; Acute Respiratory Distress Syndrome, AHI; Acute Heart Injury, RI; Renal Impairment/Injury, HI; Hepatic Impairment/Injury, SI; Secondary Infection, Sh; Shock, RF; Respiratory Failure, MDS; Multiorgan Dysfunction Syndrome
Treatment: AvT; Antiviral Therapy (not specified), LR; Lopinavir & Ritonavir, Um; Umifenovir, Fav; Favipiravir, IFN; Interferon, Ig; Immunoglobulin, Os; Oseltamivir, Rv; Ribavirin, Ster; Glucocorticoids/Corticosteroids, AbT; Antibiotic Therapy (not specified), Azi; Azithromycin, Cef; Ceftriaxone, Moxi; Moxifloxacin, Lin; Linezolid, HyC; Hydroxychloroquine, Hep; Heparin, Toc; Tocilizumab, NCa; Nasal Cannula, RRT; Renal Replacement Therapy, VS; Vasopressor Support, CPR; CPR
MV that was not specified; invasive or non-invasive
Other Treatments: HT; Hormone Therapy, VD; Vasoactive Drugs, TCM; Traditional Chinese Medicine, Hem; Hemodialysis, ThyF; Thymalfasin, MA; Mucoactive agent/Expectorant, ThyP; Thymopentin, ECMO; Extracorporeal Membrane Oxygenation, RRT; Renal Replacement Therapy, Chlor; Chloroquine, SA; Serum Albumin, PPI; Proton Pump Inhibitor